Knowledge Ecology International

As part of the World Trade Organization’s (WTO) technical assistance and capacity building program, on Thursday, 26 February 2015, the WTO Secretariat convened a Symposium on the TRIPS Agreement for TRIPS Council Members and Observers which brought together negotiators from the 1986–94 Uruguay Round to discuss how the Round introduced intellectual property norms into the architecture of the multilateral trading system. In addition, other experts were brought in to discuss what has happened since the introduction of the TRIPS Agreement, and what augurs for the future.

Continue Reading →

St Jude holds 24 patents with influenza in the specification, that also disclose US government rights. Some of these were discussed here: /node/2188

PAT. NO. Title
1 8,574,592 Modified influenza virus for monitoring and improving vaccine efficiency
2 8,551,481 Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody
3 8,309,099 DNA transfection system for the generation of negative strand RNA virus
Continue Reading →

Our 2009 FOIA request, and 42 pages of CDC emails debating what to give us.

/misc-docs/FOIA/14-01041-cdc-foia-frequest-2009.pdf

The February 17, 2015 cover letter from CDC.
/wp-content/uploads/CDC_17feb2015_FOIA_CoverLetter.pdf

The 184 page CDC foia response, which we received in February 2015. Note that we were particularly interested in the patent issues related to reverse genetics.

Continue Reading →

At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: /ustr/special301).

Continue Reading →

At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: /ustr/special301).

Continue Reading →

At the February 24, 2015 USTR hearing on Special 301, KEI asked to provide supplemental comments on R&D for the record, and KEI was separately asked by USTR to provide comments on online pharmacies, and by DHHS to comment on the relationship between emergencies and compulsory licensing. (The KEI page on Special 301 is here: /ustr/special301).

Continue Reading →

The following statement was delivered by the European Union on Tuesday, 24 February 2015 at the WTO TRIPS Council during discussions on “Concerns with respect to proposals for plain packaging of tobacco products in the United Kingdom and Ireland”.

Continue Reading →

On Wednesday February 24, 2015, the United States Trade Representative (USTR) Special 301 Committee held its annual public meeting following written comments sent earlier by trade associations, corporations and a few public interest groups that follow trade and intellectual property.

Continue Reading →

On February 24, 2015, the USTR convened the Special 301 Review, taking testimony almost exclusively from witnesses representing large corporate rights holders. Over the course of the three-and-a-half hour hearing, groups such as Phrma, NAM, IPO, and the misleadingly-named Alliance for Fair Trade with India (an alliance comprised of groups such as Phrma, NAM, MPAA and many other similar groups) as well as foreign-owned multinational Bridgestone, pushed for the watch-listing of countries that fail to implement TRIPS+ measures. Continue Reading →

On Tuesday, 24 February 2015, Bangladesh, on behalf of the LDC Group, presented the submission of the LDC Group on an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for LDC Members for Certain Obligations with Respect to Pharmaceutical Products in the following impassioned statement.

ANY OTHER BUSINESS

EXTENSION OF THE TRANSITION PERIOD UNDER ARTICLE 66.1 OF THE TRIPS AGREEMENT FOR LEAST-DEVELOPED COUNTRY MEMBERS FOR CERTAIN OBLIGATIONS WITH RESPECT TO PHARMACEUTICAL PRODUCTS

Mr. Chair

Continue Reading →